CTOR vs HSIC · rev $7.1M vs P/E 24, rev $6.83B
Citius Oncology, Inc. (CTOR) versus Henry Schein Inc (HSIC) — a side-by-side from cached financials, not a winner call.
Citius Oncology, Inc. (CTOR) is a drug manufacturers - specialty & generic company listed on US.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Latest reported CTOR revenue for 2026-06-30 was $7.1M. Net income was -$41.1M. Revenue was up 26.6% from 2026-03-31 to 2026-06-30. CTOR currently screens at market cap $105.2M.
Latest reported HSIC revenue for 2026-06-27 was $6.83B. Net income was $201.0M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
CTOR currently screens at market cap $105.2M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Not investment advice. Open the CTOR and HSIC stock pages for the full models.
Not investment advice.